/
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
$58.18
$0.35 (-0.60%)
EOD Jul 17, 2026
66.31% operating margin is above average. ROIC at 6.73%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue declined 0.5% YoY. The question is whether this is cyclical or a structural shift.
At 31x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
30.6x earnings. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.42B
▼ -0.5% YoY
Net Income (TTM)
$826M
▼ -10.2% YoY
Op. Margin
65.61%
▲ +11.6pp YoY
ROIC
6.81%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$2.61B
▼ -10.1% YoY
Net Debt
$8.37B
Cash & Equiv.
$608M
5Y CAGR: +3.6%
Continue Research
At a P/E of 30.6, Royalty Pharma (RPRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Royalty Pharma scores 19/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Royalty Pharma scores 19 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 65.6% operating margin and a 6.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh RPRX's valuation and scores 19/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.